Viking Thera VKTX

$25.83 -0.55 (-2.08%)

Valuation

Market cap
3,365,113,000
Revenue TTM
$0
Net income TTM
$-359,640,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
3,524,500
Avg volume
5,299,908
Day's range
$25.66 – $26.79
Shares out
125,987,000
Stochastic %K
37%
Beta
0.66
Analysts
Strong Sell
Price target
$91.95

Price

Company profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as...

Show more

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 704 4660
Website
https://www.vikingtherapeutics.com
Address
9920 Pacific Heights Boulevard, Suite 350, San Diego, United States

Latest news

Stocktwits

parrotineum Oct 22, 10:41 PM
$VKTX “The FTC had concerns that the structure of the Novo Nordisk proposals may violate the procedural provisions of the HSR Act if the parties consummated the issuance of the preferred stock to Novo Nordisk without first filing for premerger review as the HSR Act required. The FTC Letter, however, expressly stated that the FTC and its staff were not taking any position on the proposed transaction’s competitive effects, or whether it is lawful under substantive antitrust laws.” Direct source from SEC filing: https://www.sec.gov/Archives/edgar/data/2040807/000119312525273435/d94128ddefa14a.htm
1 replies
SurgUk Oct 22, 10:29 PM
$VKTX looks like a big Pharma will buy this in strategic buyout - NOV DEC as other patents run out - (Polymarket have priced in roughly a 38.5% probability that Viking is acquired before 2027 - my view is greater than 50%) Caveat qui vendit
0 replies
RunGal Oct 22, 10:10 PM
$VKTX “The role is responsible for developing, implementing, and maintaining phase-appropriate, risk-based GCP quality systems, processes, and governance that support reliable clinical data, protection of clinical trial participants, and advancement of clinical programs toward regulatory submissions and inspections.” https://recruiting.paylocity.com/Recruiting/Jobs/Details/4605810
0 replies
longshort00 Oct 22, 9:38 PM
$VKTX https://x.com/pharmdca/status/2113372163592044804?s=61&t=t-QB8_bW7By4vZOYi08yMQ
3 replies
DG20 Oct 22, 8:47 PM
$VKTX Bolt on could also be a combination done with a current asset that NVO owns such as Cagrilinitide. NVO made a huge mistake betting on Amylin instead of GIP. Every co-agonist to GLP worsens side effects EXCEPT GIP. VK2735 and Cagrilinitide are both ph3 assets abd could relatively easily be combined to make a triple agonist that’s more efficacious and tolerable than Retatrutide. Granted VK2735 is more than sufficient on its own. No one needs pipeline refresh more than NVO as their late stage assets Cagrisema and Amycretin have genuine tolerability issues…
1 replies
vu_jade Oct 22, 8:24 PM
$VKTX way oversold short term, great long term buy and hold. Better financial position than it was a few weeks ago. VK2735 advancing in development. Better days ahead. #SKOL
0 replies
Randini Oct 22, 8:24 PM
$VKTX https://finance.yahoo.com/markets/article/moderna-stock-crashes-as-leaked-melanoma-data-threatens-its-record-august-rally-191447054.html
0 replies
ReneDif Oct 22, 8:21 PM
$VKTX The next catalyst is the Q3 earnings call. Hopefully, BL will come out of hiding and provide some clarity on the future strategy and plans for commercialization and/or a partnership. It’s interesting that the corporate presentation has been updated to include “ongoing partnership discussions” for VK2809. Perhaps we’ll get some hints here that could also be interpreted in the context of VK2735 (one can always hope). Sometime between November and January, we should hopefully get the Phase 1 amylin data. Beyond that, it’s a waiting game until the summer, when we expect the Phase 3 readouts. If we get some positive announcements, I don’t think it will take much to lift the stock significantly from current levels. And if partnership or M&A rumors start circulating, things could move very quickly. But right now, the stock is plagued by short sellers and a degree of distrust in management’s decisions, combined with a lack of communication. That’s why we’re stuck at these levels.
2 replies